YOU ARE HERE: LAT HomeCollectionsAllergan Inc

Allergan Inc

January 24, 2006 | From Reuters
Botox maker Allergan Inc. said it was extending its $3.2-billion offer to buy breast implant maker Inamed Corp. because it had yet to get antitrust clearance from regulators. The offer is now set to expire at 8 p.m. on Feb. 7; it had been set to expire today. Irvine-based Allergan and Santa Barbara-based Inamed said they were working with the Federal Trade Commission to complete the sale of Inamed's license for Reloxin, a botulism toxin product.
June 12, 1996
The Orange County chapter of the American Red Cross has received two grants totaling $11,000 for its disaster preparedness programs. Pacific Mutual Foundation of Newport Beach made a $5,000 contribution, and Allergan Inc. of Irvine gave $6,000. Dolores Churchill, the chapter's chairwoman, said the Red Cross recently spent $30,000 to help 37 families who were left homeless when a May 19 blaze burned their Garden Grove apartment complex.
August 27, 1991
Allergan Inc. has won U.S. and Canadian marketing rights to an anti-acne medication sold in Europe by Schering AG of Germany, the company said Monday. Herbert Laboratories, the skin care division of Allergan, will begin clinical studies on the topical compound, azelaic acid, and seek FDA approval, a process expected to take at least three years, said Allergan spokesman Jeff D'Eliscu. Schering has been marketing azelaic acid as Skinoren cream in Europe, the company said.
January 22, 1998 | Dow Jones
Illinois-based Akorn Inc. said Wednesday it agreed to buy the ophthalmic pharmaceutical product Paremyd from Allergan Inc. for an undisclosed amount of cash. Paremyd is used for pupil dilation in routine diagnostic procedures, but it has been off the market since 1996 due to a raw material shortage.
July 27, 1995
Allergan Inc., an Irvine eye care products company, said Wednesday it has signed an option agreement with Peptech Ltd., in England, for development and commercial marketing of products based on a Peptech dermatological product. Allergan will have first rights to license potential applications in the fields of ophthalmology and oncology. "The collaboration with Peptech is yet another example of establishing strategic partnerships to pursue promising new technologies," said Richard M.
July 13, 2005 | From Bloomberg News
Pharmacopeia Drug Discovery Inc. said it would work with Allergan Inc. to develop treatments for a leading cause of blindness that might compete with drugs from Pfizer Inc., Eyetech Pharmaceuticals Inc. and Genentech Inc. Pharmacopeia and Allergan, maker of the Botox wrinkle treatment, said they would collaborate on drugs for age-related degeneration of the eye's macula.
December 21, 1994
Allergan Inc. said Tuesday that its venture with Ligand Pharmaceuticals Inc. will go public. Shareholders in the two companies will be offered $32.5 million worth of stock in the joint venture, called Ligand and Allergan Ligand Retinoid Therapeutics Inc. The research and development venture between San Diego-based Ligand and Allergan, based in Irvine, began in June, 1992, to develop a treatment for cancer.
January 19, 2005 | From Bloomberg News
Allergan Inc., the maker of Botox injections to smooth wrinkles, said it would consolidate its European research and development operations to save as much as $9 million a year. Operations at the plants to be closed will be moved to Britain, Ireland and the U.S., Irvine-based Allergan said. The closings, which also affect some sales operations, will cost the company about $50 million to $60 million through the second quarter of 2006. Shares of Allergan rose $1.24, or 1.6%, to $81.02 on the
July 25, 1997
Allergan Inc. said Thursday it has agreed to sell its ophthalmic pharmaceutical manufacturing facility in Pomezia, Italy, to a management team there. Allergan will also sell certain ophthalmic pharmaceutical products to the management team led by Emidio Fedeli, currently operations director of Allergan S.p.A. The sale is part an effort by Allergan to streamline operations. After the sale, the new company will be called Tubilux Pharma S.p.A.
Los Angeles Times Articles